Metraipolis › archive › dc_fcd7f99b53a2

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers — Europe PMC PMID:41463269

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41463269
DOI
10.3390/cancers17244021
License (as archived)
solo-consultazione
Archived
2026-11-07T13:53:55.974Z
SHA-256 of the archived text
9c23a7355c440e62a539836d560fc7b680f7d01418731c1e1603526935c82694
Stable URL of this page
https://metraipolis.com/documento/dc_fcd7f99b53a2

How to cite

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers — Europe PMC PMID:41463269 — Europe PMC (en), https://europepmc.org/article/MED/41463269 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fcd7f99b53a2 (Metraipolis archive dc_fcd7f99b53a2, sha256 9c23a7355c440e62a539836d560fc7b680f7d01418731c1e1603526935c82694)
BibTeX
@misc{dcfcd7f99b53a2,
  title = {HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers — Europe PMC PMID:41463269},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41463269},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fcd7f99b53a2; sha256 9c23a7355c440e62a539836d560fc7b680f7d01418731c1e1603526935c82694},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41463269. Agents can read the archived copy with the MCP tool read_document.